What is OneMRI?
Founded in October 2024 by Dr. Vu Tran, Andrew Barnes, and Gopi Sara, OneMRI operates at the intersection of advanced medical imaging and preventative health. The company provides a national service dedicated to whole-body MRI scans, a diagnostic modality capable of identifying over 500 health conditions. These include early-stage cancers, metabolic disorders, autoimmune conditions like multiple sclerosis, and structural issues such as spinal degeneration and brain aneurysms.
By democratizing access to high-fidelity diagnostic imaging, OneMRI is shifting the healthcare paradigm from reactive treatment to proactive health management. The company's market position is defined by its commitment to early detection, utilizing sophisticated technology to provide actionable health insights that were previously inaccessible to the general public on a national scale.
How much funding has OneMRI raised?
OneMRI has raised a total of $1.6M across 1 funding round:
Seed
$1.6M
Seed (2025): $1.6M with participation from Archangel Ventures, Tribe Global Ventures, OIF Ventures, Salus Ventures, and Antler
Key Investors in OneMRI
Tribe Global Ventures
A B2B venture capital firm that assists tech companies in scaling to the UK and USA markets, providing strategic support and founder development.
OIF Ventures
A venture capital firm managing over $500 million in assets, focused on empowering technology founders with industry expertise and deep networks.
Salus Ventures
A seed-stage investment firm specializing in mission-driven founders addressing critical challenges at the intersection of enterprise and national security.
What's next for OneMRI?
With the recent infusion of capital, OneMRI is poised to enter a phase of rapid operational scaling. The strategic roadmap likely involves the deployment of additional imaging centers and the integration of advanced data analytics to streamline the diagnostic process. As the company matures, the focus will shift toward optimizing patient throughput and strengthening partnerships within the broader healthcare ecosystem.
The involvement of high-caliber investors suggests a long-term commitment to building a sustainable, high-growth enterprise. Future milestones will likely center on clinical validation, technological refinement, and the potential for international expansion, as the company continues to address the critical demand for preventative diagnostic solutions in an increasingly health-conscious market.
